Molecular genetic and immunotherapeutic targets in metastatic melanoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular genetic and immunotherapeutic targets in metastatic melanoma
Authors
Keywords
Melanoma, BRAF, Targeted therapy, Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), Programmed death 1 (PD-1), Immunotherapy
Journal
VIRCHOWS ARCHIV
Volume 471, Issue 2, Pages 281-293
Publisher
Springer Nature
Online
2017-03-29
DOI
10.1007/s00428-017-2113-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
- (2017) Reinhard Dummer et al. LANCET ONCOLOGY
- Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma
- (2017) Claire Franczak et al. Molecular Diagnosis & Therapy
- The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond
- (2016) Ziqiang Zhu et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma
- (2016) Kim Margolin CURRENT TREATMENT OPTIONS IN ONCOLOGY
- PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation
- (2016) Ian A Cree et al. HISTOPATHOLOGY
- BRAFV600EandNRASQ61L/Q61Rmutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting
- (2016) Hojabr Kakavand et al. HISTOPATHOLOGY
- Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature
- (2016) Muhammad Ahmed Farooq Anwar et al. JOURNAL OF SURGICAL RESEARCH
- Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients
- (2016) Teofila Seremet et al. Journal of Translational Medicine
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry
- (2016) William Bruno et al. Oncotarget
- Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
- (2016) Jake S. O’Donnell et al. Genome Medicine
- Detection of BRAF Mutations Using a Fully Automated Platform and Comparison with High Resolution Melting, Real-Time Allele Specific Amplification, Immunohistochemistry and Next Generation Sequencing Assays, for Patients with Metastatic Melanoma
- (2016) Alexandre Harlé et al. PLoS One
- NF1 Mutations Are Common in Desmoplastic Melanoma
- (2015) Thomas Wiesner et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
- (2015) A. Santiago-Walker et al. CLINICAL CANCER RESEARCH
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
- (2015) Kathleen M. Mahoney et al. CLINICAL THERAPEUTICS
- Treatment of NRAS-Mutant Melanoma
- (2015) Douglas B. Johnson et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
- (2015) Douglas B. Johnson et al. EUROPEAN JOURNAL OF CANCER
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma
- (2015) Marius Ilie et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France)
- (2015) E. Long et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- BRAFV600E immunopositive Melanomas Show Low Frequency of Heterogeneity and Association With Epithelioid Tumor Cells
- (2015) Ivana Verlinden et al. MEDICINE
- The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia
- (2014) Boris C. Bastian Annual Review of Pathology-Mechanisms of Disease
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy
- (2014) Joshua R Bradish et al. MODERN PATHOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Targeting RAS–ERK signalling in cancer: promises and challenges
- (2014) Ahmed A. Samatar et al. NATURE REVIEWS DRUG DISCOVERY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
- (2013) L Heinzerling et al. BRITISH JOURNAL OF CANCER
- Immunotherapy for advanced melanoma: Fulfilling the promise
- (2013) Helen Gogas et al. CANCER TREATMENT REVIEWS
- Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
- (2013) C. Robert et al. CLINICAL CANCER RESEARCH
- Targeting Activated KIT Signaling for Melanoma Therapy
- (2013) Boris C. Bastian et al. JOURNAL OF CLINICAL ONCOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma
- (2012) Georgina V. Long et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
- (2012) A. M. Menzies et al. CLINICAL CANCER RESEARCH
- BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
- (2012) Maria Colombino et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of BRAF p.V600E Mutations in Melanomas
- (2012) Emeline Colomba et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Evaluation of BRAF Mutation Testing Methodologies in Formalin-Fixed, Paraffin-Embedded Cutaneous Melanomas
- (2012) Johanne Lade-Keller et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- (2011) Rui-Ru Ji et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- KIT as a Therapeutic Target in Metastatic Melanoma
- (2011) Richard D. Carvajal JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
- (2011) C. Garbe et al. ONCOLOGIST
- Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis
- (2010) S. Mocellin et al. JNCI-Journal of the National Cancer Institute
- Mutations inGNA11in Uveal Melanoma
- (2010) Catherine D. Van Raamsdonk et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic and morphologic features for melanoma classification
- (2010) Sigrid M. C. Broekaert et al. Pigment Cell & Melanoma Research
- Improving Melanoma Classification by Integrating Genetic and Morphologic Features
- (2008) Amaya Viros et al. PLOS MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started